Cargando…
Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma
OBJECTIVES: Previous pharmacogenetics studies showed that genetic variants could be indicative of the response to chemotherapy. We aimed to investigate whether variants of FasL, MSH2, ABCC5, CASP3 and CYP3A4 are associated with the outcome after chemotherapy-based treatment in osteosarcoma. METHODS:...
Autores principales: | Xu, Leilei, Xia, Chao, Sun, Qi, Sheng, Fei, Xiong, Jin, Wang, Shoufeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066469/ https://www.ncbi.nlm.nih.gov/pubmed/30065912 http://dx.doi.org/10.1016/j.jbo.2018.04.003 |
Ejemplares similares
-
The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability
por: Henkler, Frank, et al.
Publicado: (2005) -
The Fas/FasL System in Reproduction: Survival and Apoptosis
por: Mor, Gil, et al.
Publicado: (2002) -
A promoter variant of lncRNA GAS5 is functionally associated with the development of osteosarcoma
por: Xu, Leilei, et al.
Publicado: (2018) -
Role of the Fas/FasL pathway in HIV or SIV disease
por: Poonia, Bhawna, et al.
Publicado: (2009) -
The signaling pathways by which the Fas/FasL system accelerates oocyte aging
por: Zhu, Jiang, et al.
Publicado: (2016)